Tag: AstraZeneca
AstraZeneca Halts Phase III eVOLVE-Lung02 Trial of Volrustomig in Advanced Lung Cancer
AstraZeneca has announced it is stopping its Phase III eVOLVE-Lung02 study, which was testing volrustomig combined with chemotherapy as a first-line treatment for metastatic non-small cell...
Pathos AI Expands Oncology Pipeline Through Strategic Deals with Alphamab and AstraZeneca
Pathos AI announced two separate licensing and co-development agreements with Alphamab Oncology and AstraZeneca, expanding its clinical-stage pipeline of targeted cancer therapies using its proprietary platform,...
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo announced that the US Food and Drug Administration (FDA) has approved Datroway(datopotamab deruxtecan) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC)...
